Refractory, high risk, and far away
71anti-CD38-refractory del(17p) myelomarenal impairment, AFfar from the bispecific center
Refractory status, or the constraints around him?
37%
Refractory status
63%
Comorbidity and distance
What matters now
Retrospective analyses now identify cure in multiple myeloma after CAR T-cell therapy. One-third of evaluated patients remained disease-free.
71anti-CD38-refractory del(17p) myelomarenal impairment, AFfar from the bispecific center
Refractory status, or the constraints around him?
37%
Refractory status
63%
Comorbidity and distance
61newly diagnosed myeloma, transplant-eligiblet(4;14), ECOG 1, reduced creatinine clearance
One finding, or the panel together?
56%
Findings read separately
44%
The cytogenetic panel together
58standard-risk myeloma, MRD-negative on maintenancefeels well, no longitudinal plan written
Depth and risk, or how she feels?
44%
Response depth and risk
56%
Regimen, imaging and symptoms
78transplant-ineligible myelomaECOG 2, heart failure, diabetes, polypharmacy, limited support
Measure her fitness, or manage around it?
48%
A fitness measurement
52%
Comorbidity, support and stage
67fitfirst biochemical relapse after quadruplet, transplant and maintenanceneuropathy
The exposure, or the disease behavior?
65%
Biology, duration and timing
36%
The recent exposure
What matters now
Retrospective analyses now identify cure in multiple myeloma after CAR T-cell therapy. One-third of evaluated patients remained disease-free.
5 Real World Scenarios
71anti-CD38-refractory del(17p) myelomarenal impairment, AFfar from the bispecific center
Refractory status, or the constraints around him?
Where does the evidence land?
37%
Refractory status
63%
Comorbidity and distance
61newly diagnosed myeloma, transplant-eligiblet(4;14), ECOG 1, reduced creatinine clearance
One finding, or the panel together?
Where does the evidence land?
56%
Findings read separately
44%
The cytogenetic panel together
58standard-risk myeloma, MRD-negative on maintenancefeels well, no longitudinal plan written
Depth and risk, or how she feels?
Where does the evidence land?
44%
Response depth and risk
56%
Regimen, imaging and symptoms
78transplant-ineligible myelomaECOG 2, heart failure, diabetes, polypharmacy, limited support
Measure her fitness, or manage around it?
Where does the evidence land?
48%
A fitness measurement
52%
Comorbidity, support and stage
67fitfirst biochemical relapse after quadruplet, transplant and maintenanceneuropathy
The exposure, or the disease behavior?
Where does the evidence land?
65%
Biology, duration and timing
36%
The recent exposure